Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

Lancet. 2019 Jan 5;393(10166):3-5. doi: 10.1016/S0140-6736(18)32824-1. Epub 2018 Nov 10.

Authors

Subodh Verma¹, Peter Jüni², C David Mazer²

Affiliations

¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto M5B 1W8, ON, Canada; Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.

PMID: 30424891
DOI: 10.1016/S0140-6736(18)32824-1

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Canagliflozin
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Secondary Prevention
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin